Fuzzy tricentric pharmacophore fingerprints.: 2.: application of topological fuzzy pharmacophore triplets in quantitative structure-activity relationships

被引:32
作者
Bonachera, Fanny [1 ]
Horvath, Dragos [1 ]
机构
[1] Univ Sci & Technol Lille, Unite Glycobiol Struct & Fonct, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France
关键词
D O I
10.1021/ci7003237
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Topological fuzzy pharmacophore triplets (2D-FPT), using the number of interposed bonds to measure separation between the atoms representing pharmacophore types, were employed to establish and validate quantitative structure-activity relationships QSAR). Thirteen data sets for which state-of-the-art QSAR models were reported in literature were revisited in order to benchmark 2D-FPT biological activity-explaining propensities. Linear and nonlinear QSAR models were constructed for each compound series (following the original author's splitting into training/validation subsets) with three different 2D-FPT versions, using the genetic algorithm-driven Stochastic QSAR sampler (SQS) to pick relevant triplets and fit their coefficients. 2D-FPT QSARs are computationally cheap, interpretable, and perform well in benchmarking. In a majority of cases (10/13), default 2D-FPT models validated better than or as well as the best among those reported, including 3D overlay-dependent approaches. Most of the analogues series, either unaffected by protonation equilibria or unambiguously adopting expected protonation states, were equally well described by rule- or pK(a)-based pharmacophore flagging. Thermolysin inhibitors represent a notable exception: pK(a)-based flagging boosts model quality, although-surprisingly-not due to proteolytic equilibrium effects. The optimal degree of 2D-FPT fuzziness is compound set dependent. This work further confirmed the higher robustness of nonlinear over linear SQS models. In spite of the wealth of studied sets, benchmarking is nevertheless flawed by low intraset diversity: a whole series of thereby caused artifacts were evidenced, implicitly raising questions about the way QSAR studies are conducted nowadays. An in-depth investigation of thrombin inhibition models revealed that some of the selected triplets make sense (one of these stands for a topological pharmacophore covering the P-1 and P-2 binding pockets). Nevertheless, equations were either unable to predict the activity of the structurally different ligands or tended to indiscriminately predict any compound outside, the training family to be active. 2D-FPT QSARs do however not depend on any common scaffold required for molecule superimposition and may in principle be trained on hand of diverse sets, which is a must in order to obtain widely applicable models. Adding (assumed) inactives of various families for training enabled discovery of models that specifically recognize the structurally different actives.
引用
收藏
页码:409 / 425
页数:17
相关论文
共 33 条
[1]   Integrating research and development: the emergence of retional drug design in the pharmaceutical industry [J].
Adam, Matthias .
STUDIES IN HISTORY AND PHILOSOPHY OF SCIENCE PART C-STUDIES IN HISTORY AND PHILOSOPHY OF BIOLOGICAL AND BIOMEDIAL SCIENCES, 2005, 36 (03) :513-537
[2]   Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors [J].
Barreca, ML ;
Ferro, S ;
Rao, A ;
De Luca, L ;
Zappalà, M ;
Monforte, AM ;
Debyser, Z ;
Witvrouw, M ;
Chimirri, A .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :7084-7088
[3]   Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa [J].
Böhm, M ;
Stürzebecher, J ;
Klebe, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (03) :458-477
[4]   Fuzzy tricentric pharmacophore fingerprints.: 1.: Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes [J].
Bonachera, Fanny ;
Parent, Benjamin ;
Barbosa, Frederique ;
Froloff, Nicolas ;
Horvath, Dragos .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2006, 46 (06) :2457-2477
[5]   Design and discovery of novel, potent pyrazinone-based thrombin inhibitors with a solubilizing amino P1-P2-linker [J].
Bulat, S. ;
Bosio, S. ;
Papadopoulos, M. A. ;
Cerezo-Galvez, S. ;
Grabowski, E. ;
Rosenbaum, C. ;
Matassa, V. G. ;
Ott, I. ;
Metz, G. ;
Schamberger, J. ;
Sekul, R. ;
Feurer, A. .
LETTERS IN DRUG DESIGN & DISCOVERY, 2006, 3 (05) :289-292
[6]   Alkylation of heme by artemisinin, an antimalarial drug [J].
Cazelles, J ;
Robert, A ;
Meunier, B .
COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE II FASCICULE C-CHIMIE, 2001, 4 (02) :85-89
[7]  
*CHEM, PMAPP US GUID
[8]   The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor [J].
Chirgadze, NY ;
Sall, DJ ;
Klimkowski, VJ ;
Clawson, DK ;
Briggs, SL ;
Hermann, R ;
Smith, GF ;
GiffordMoore, DS ;
Wery, JP .
PROTEIN SCIENCE, 1997, 6 (07) :1412-1417
[9]   The CoMFA steroids as a benchmark dataset for development of 3D QSAR methods [J].
Coats, EA .
PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, 1998, 12 :199-213
[10]   COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967